Valneva SE (NASDAQ:VALN) Sees Significant Growth in Short Interest

Valneva SE (NASDAQ:VALN) was the recipient of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 30,600 shares, a growth of 111.0% from the November 15th total of 14,500 shares. Based on an average daily volume of 23,500 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.0% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright dropped their price objective on shares of Valneva from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, October 11th.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC increased its position in Valneva SE (NASDAQ:VALN) by 42.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 88,252 shares of the company’s stock after buying an additional 26,248 shares during the quarter. AlphaCentric Advisors LLC owned about 0.13% of Valneva worth $649,000 at the end of the most recent reporting period. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Stock Down 0.8 %

Shares of NASDAQ VALN opened at $3.93 on Friday. The firm’s 50-day simple moving average is $5.07 and its 200 day simple moving average is $6.52. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. Valneva has a fifty-two week low of $3.82 and a fifty-two week high of $10.93.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.